genOway
Lyon-based company creating genetically engineered and humanized rodent models, with catalog models and in vivo research services.
18 contract research organizations in our directory list at least one of Antibody Programs, AAV Biodistribution, Oligonucleotide Therapeutics, Cell Therapy, Ligand Binding Assays, Immunotoxicology, Antibody Discovery, Bispecific Antibody Development or ADC Development, across 6 countries. 13 report GLP capability and 3 report AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.
Biologics include monoclonal and bispecific antibodies, antibody-drug conjugates, fusion proteins, peptides, gene therapies, cell therapies and oligonucleotides. Their preclinical programs are shaped by ICH S6(R1), which asks for safety testing in a pharmacologically relevant species: one in which the molecule binds its target and produces the expected effect. For many human-specific antibodies that is only the nonhuman primate, and for some it is no species at all, which means surrogate molecules or genetically modified mice.
Several capabilities separate CROs that handle biologics well. Species selection relies on binding and functional data and, for antibodies, tissue cross-reactivity studies. Bioanalysis uses ligand binding assays for PK and anti-drug antibody (ADA) assays for immunogenicity, which can change exposure in repeat-dose studies. Gene and cell therapies add biodistribution, shedding and persistence endpoints, and oligonucleotides bring class-specific findings and often require CNS delivery routes.
If you are asking which CROs offer in vivo pharmacology for antibody programs, start with the antibody programs list below and confirm two things with each lab: that its models express a target your antibody binds, and that it can measure both drug levels and ADA in the same animals.
Showing 18 CROs. Order rotates daily so no lab is permanently listed first.
Lyon-based company creating genetically engineered and humanized rodent models, with catalog models and in vivo research services.
Molecular testing laboratory supporting cell and gene therapy programs with GLP qPCR and ddPCR assays for biodistribution, shedding and vector persistence, plus assay development and validation.
Barcelona bioanalytical laboratory supporting preclinical and clinical studies with regulated LC-MS/MS and ligand binding assays.
Spanish analytical and bioanalytical CRO providing GLP small and large molecule bioanalysis and CMC testing.
Preclinical CRO with GLP laboratories near Budapest and offices in Munich, offering safety assessment, ADME-PK, bioanalysis and pharmacodynamic models.
Bioanalytical CRO with laboratories in the US, UK and Australia offering small and large molecule assays, immunogenicity and biomarker work for nonclinical and clinical studies.
Vector design and manufacturing company that also offers AAV biodistribution profiling services, including barcoded multiplex studies in rodents and NHPs.
North Carolina CRO specializing in immunotoxicology, including GLP immune function assays for drugs, chemicals and biologics.
UK bioanalytical CRO providing regulated small and large molecule bioanalysis for preclinical and clinical studies.
Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…
Large molecule bioanalytical laboratory providing GLP and GCLP pharmacokinetic, immunogenicity, biomarker and cell-based assays, with labs in the US and Europe.
Preclinical CRO in West Michigan specializing in targeted CNS delivery. Long track record supporting intrathecal, intracerebroventricular and cisterna magna dosing, CSF and tissue distribution, pharmacokinetics and…
Bioanalytical and biomarker CRO supporting preclinical and clinical programs with LC-MS/MS, ligand binding, flow cytometry and cell and gene therapy assays, with sites in the US and France.
Animal model company offering custom genetically engineered rodents together with in vivo pharmacology and AAV services, with operations in the US and China.
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
French CRO specializing in analytics for gene and cell therapies, including GLP biodistribution, vector shedding and anti-AAV immunogenicity assays.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Connecticut bioanalytical laboratory offering LC-MS/MS and ligand binding assay development, validation and sample analysis for preclinical and clinical programs.
ICH S6(R1) asks for toxicology in a species where the biologic is pharmacologically active. The usual evidence combines target sequence homology, binding affinity to the human and cynomolgus targets measured side by side (for example by SPR), and functional activity in cynomolgus cells compared with human cells, such as receptor signaling or effector function. A tissue cross-reactivity study adds information on binding across tissues. If the cynomolgus target is not bound, a surrogate molecule or transgenic model may be needed.
Preclinical antibody characterisation usually covers binding affinity and kinetics, species cross-reactivity, epitope and specificity work, Fc receptor binding and effector function, and in vitro potency assays. Some labs listed here pair this with in vivo pharmacology, PK and immunogenicity testing, which keeps species selection and dose planning in one place.